AccurKardia
AccurKardia is a New York-based medical AI software company that builds FDA-cleared, device-agnostic AI-ECG interpretation software (AccurECG) for hospitals, diagnostic testing facilities, cardiac monitoring companies, and medical device makers, with investigational extensions into aortic stenosis, hyperkalemia, and cardiac amyloidosis detection.
- Company typePrivate
- Founded2019
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What AccurKardia does
AccurKardia is a New York-based medical AI software company building a device-agnostic platform that uses deep learning models trained on standard 12-lead ECG signals to interpret cardiac rhythms and to surface hidden diagnostic information within the ECG. Its flagship product, AccurECG (with the current generation AccurECG 2.0), received FDA 510(k) clearance (K252361) in January 2026 and classifies ECGs across 13 rhythm categories including atrial fibrillation, atrial flutter, and ventricular tachycardia. The same ECG-as-biomarker foundation is being extended into investigational applications: AK-AVS, an AI-ECG model that detects aortic stenosis up to 4.5 years before transcatheter aortic valve replacement and received FDA Breakthrough Device Designation in 2024; AK+ Guard, an AI-powered hyperkalemia detection software currently in a multicenter U.S. clinical pilot study of more than 150 patients; and a granted patent (June 2026) covering machine-learning detection of cardiac amyloidosis from standard 12-lead ECGs.
AccurKardia monetizes through B2B software licensing of AccurECG/AccurECG 2.0 to hospitals, diagnostic testing facilities, cardiac monitoring companies, and medical device makers, with pricing that is not publicly disclosed but offered on an advisory basis to qualified healthcare professionals and structured around annual, volume-based deployments. A parallel OEM/embedded distribution motion licenses the software into third-party hardware — most prominently HeartBeam's credit-card-sized 3D ECG device under an April 2025 strategic collaboration targeting preventive cardiology and concierge medicine — providing a channel-partner lever for embedded distribution. As of early 2026 the company has disclosed approximately $14 million in cumulative funding across rounds from 2019 through March 2026, including a $2.7 million seed led with participation from Mayo Clinic and Popular Impact Fund, a $5.3 million round in March 2026, and a leadership and senior advisory bench drawing from The Texas Heart Institute, Solventum, Medtronic, Edwards Lifesciences, iRhythm, and BioTelemetry.
AccurKardia firmographics
Firmographics- Name
- AccurKardia
- Legal name
- AccurKardia, Inc.
- Website
- https://accurkardia.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AccurKardia is a New York-based medical AI software company that builds FDA-cleared, device-agnostic AI-ECG interpretation software (AccurECG) for hospitals, diagnostic testing facilities, cardiac monitoring companies, and medical device makers, with investigational extensions into aortic stenosis, hyperkalemia, and cardiac amyloidosis detection.
- Ownership category
- akta.pro rank
AccurKardia industry classification
Industry- Product category
- Cardiac Diagnostic Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Scientific and Technical Consulting Services (54169), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Services-Testing Laboratories (8734), Instruments For Meas & Testing Of Electricity & Elec Signals (3825)
- akta.pro primary industry
- Medical Billing & Coding Automation (HLACACAA)
- akta.pro secondary industries
- Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG) (HLAGAAAJ), Cardiology Telemedicine Platforms (HLALAGAB)
Keywords
Where AccurKardia is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
AccurKardia business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- AccurECG Software Licensing: B2B software licensing to healthcare ecosystem (hospitals, diagnostic testing facilities, cardiac monitoring companies, medical device makers) for FDA-cleared AccurECG/AccurECG 2.0 interpretation platform; device-agnostic deployment supports high-volume ECG interpretation. Exact pricing not publicly disclosed.
- Embedded/OEM Software Integration: Software integration and licensing deals with medical device manufacturers (e.g., HeartBeam) embedding AccurKardia's FDA-cleared ECG analysis algorithms into their hardware products for automated rhythm assessment.
- AK-AVS and AK+ Guard (Pre-Revenue / Research Use): AK-AVS and AK+ Guard are currently for research use only and have not been cleared or approved by the US FDA; revenue model not yet established for these investigational products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Annual | Quote-based B2B software licensing to qualified healthcare professionals and institutions |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
AccurKardia product offering
Product offeringCore offering
AccurKardia develops and licenses a device-agnostic AI-enabled ECG interpretation software platform. Its FDA-cleared flagship product AccurECG (and AccurECG 2.0) automates interpretation of standard 12-lead ECGs across 13 rhythm classifications, while investigational modules AK-AVS and AK+ Guard extend the platform to AI-enabled detection of aortic stenosis and hyperkalemia respectively. The software is licensed to hospitals, diagnostic testing facilities, cardiac monitoring companies, and medical device manufacturers.
Product overview
AccurKardia offers an AI-ECG platform built around one FDA-cleared flagship product, AccurECG, supplemented by two investigational AI-ECG modules, AK-AVS and AK+ Guard. AccurECG serves as the core automated ECG interpretation engine, while AK-AVS (aortic stenosis detection) and AK+ Guard (hyperkalemia detection) extend the same ECG-as-biomarker foundation to novel cardiovascular and metabolic indications. Together, the portfolio positions ECGs as a broad diagnostic biomarker that supports both traditional rhythm interpretation and earlier detection of conditions beyond standard ECG capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- AccurECG: FDA-cleared flagship AI-enabled automated ECG interpretation application (including AccurECG 2.0 version) that streamlines interpretation of ECGs.
- AK-AVS
- AK+ Guard
Products and services
- AccurECG
Quantifiable outcome
- Detects aortic stenosis up to 4.5 years before transcatheter aortic valve replacement (TAVR)
- +4 more outcomes
Companies that use AccurKardia
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
AccurKardia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability4 records
Feature5 records
AccurKardia partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, flagship and minor.
- Baylor St. Luke's Medical CentercoreClinical research partner for AccurKardia's AK-AVS study published in the European Heart Journal – Digital Health, which evaluated community-based populations and TAVR patients. The study supported evidence that the AI-ECG can detect aortic stenosis up to 4.5 years before valve replacement and predict one-year mortality risk post-TAVR.
- HeartBeamflagshipStrategic collaboration announced April 2025 to develop cardiac monitoring solutions by integrating AccurKardia's FDA-cleared ECG analysis software into HeartBeam's credit-card-sized 3D ECG device. The collaboration aims to enable automated rhythm assessment and expedite cardiac diagnosis, with subsequent plans for FDA clearance and commercialization focus on preventive cardiology and concierge practices.
- Mayo Clinic Platform AcceleratecoreAccurKardia was selected to participate in the Mayo Clinic Platform_Accelerate program for further clinical validation, and subsequently completed Cohort 3 of the program, supporting the company's clinical evidence and validation work.
- NVIDIA InceptionminorMember of NVIDIA Inception, a startup program that supports AI-focused companies with access to NVIDIA technology, expertise, and go-to-market resources.
- MedTech InnovatorminorParticipant in MedTech Innovator, a leading medtech accelerator that supports medical device and digital health startups.
- American Heart Association (AHA) Center for Health Technology & Innovation Innovators NetworkminorMember of the AHA Innovators Network, a health technology innovation community.
- AdvaMed (Advanced Medical Technology Association)minorMember of AdvaMed, the leading medical technology trade association.
- HITLABminorAffiliated with HITLAB, a digital health innovation and research organization.
- Digital Health Hub Foundationminor2024 finalist in the Digital Health Hub Awards (provider diagnostic category); engagement with the Digital Health Hub community.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
AccurKardia competitors and assessment
Company assessmentEmerging players
- HeartFlow: HeartFlow commercializes AI-driven non-invasive cardiac diagnostics (FFR-CT) and is expanding into broader AI-cardiology, representing an adjacent AI-cardiac-diagnostics peer with similar enterprise health-system GTM motion.
- Anumana: Anumana develops AI-ECG algorithms for detecting hidden cardiac conditions from standard 12-lead ECGs, overlapping with AccurKardia's AK-AVS biomarker-detection approach and supported by Mayo Clinic Platform.
- Cardiac Insight: Cardiac Insight develops AI-enabled ambulatory ECG and cardiac arrhythmia diagnostics, partially overlapping with AccurKardia's high-volume ECG interpretation focus.
- Tempus AI: Tempus AI applies AI to large-scale clinical and molecular data including cardiology; while broader than ECG, its AI-driven cardiology programs intersect thematically with AccurKardia's biomarker discovery thesis.
Direct peers
- AliveCor: AliveCor develops AI-enabled ECG products (KardiaMobile) for consumer and clinical rhythm interpretation, directly competing with AccurECG in AI-ECG rhythm classification for clinicians and patients.
- HeartBeam: HeartBeam is a credit-card-sized 3D ECG device company that has a strategic collaboration with AccurKardia to embed its ECG analysis software, making it both a partner and a closely adjacent AI-ECG player.
- Eko Health: Eko Health builds AI-powered digital stethoscope and ECG platforms with FDA-cleared cardiac analysis algorithms, competing head-to-head with AccurKardia in AI-ECG interpretation for clinicians and OEM device makers.
Broad incumbents
- Philips: Philips provides enterprise cardiology platforms (e.g., IntelliSpace ECG) with embedded ECG interpretation across large hospital installed bases, representing a major channel-partner or competitor for AccurECG.
- GE Healthcare: GE Healthcare ships ECG carts, MUSE cardiology information systems, and AI-enabled ECG interpretation embedded in hospital workflows — the dominant incumbent AccurKardia must integrate with or displace in hospitals.
- iRhythm Technologies: iRhythm (Zio) is an established ambulatory cardiac monitoring company that uses AI for ECG analysis at scale — a benchmark customer and competitor for AccurKardia's monitoring-company licensing motion.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
AccurKardia social profiles
Digital presenceAccurKardia compliance and trust
Trust signalCompliance2 records
AccurKardia financial estimates
Financial estimateRevenue estimate
Valuation estimate
AccurKardia leadership team
Management profileNumber of profiles
Profiles13 records
AccurKardia funding detail
Funding detailFunding overview
Funding rounds9 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AccurKardia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AccurKardia
What does AccurKardia do?
AccurKardia develops and licenses a device-agnostic AI-enabled ECG interpretation software platform. Its FDA-cleared flagship product AccurECG (and AccurECG 2.0) automates interpretation of standard 12-lead ECGs across 13 rhythm classifications, while investigational modules AK-AVS and AK+ Guard extend the platform to AI-enabled detection of aortic stenosis and hyperkalemia respectively. The software is licensed to hospitals, diagnostic testing facilities, cardiac monitoring companies, and medical device manufacturers.
Is AccurKardia a public or private company?
AccurKardia is a private company. It is classified as venture growth investor backed and is currently operating.
When was AccurKardia founded?
AccurKardia was founded in 2019. It employs 11 to 50 people.
Where is AccurKardia based?
AccurKardia is headquartered in New York, United States, in the North America region.
How does AccurKardia make money?
Three revenue lines are on record. AccurECG Software Licensing is the primary driver. The others are embedded/OEM Software Integration and AK-AVS and AK+ Guard (Pre-Revenue / Research Use).
Who are AccurKardia's main competitors?
Emerging players on record are HeartFlow, Anumana, Cardiac Insight and Tempus AI. Direct peers are AliveCor, HeartBeam and Eko Health. Broad incumbents are Philips, GE Healthcare and iRhythm Technologies.
Does AccurKardia have an API?
No public API is recorded for AccurKardia.
What industry is AccurKardia in?
AccurKardia's product category is Cardiac Diagnostic Software. Its primary akta.pro industry code is HLACACAA, Medical Billing & Coding Automation, with a secondary code of HLAGAAAJ, Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG). Its NAICS code is 334510 and its SIC code is 3845.